Intravenous gamma-globulin in myasthenia gravis: interaction with anti-acetylcholine receptor autoantibodies.
Clinical improvement has been observed in myasthenia gravis patients treated by intravenous immunoglobulin (IVIg). In order to investigate the mechanism of action of these IVIg, we looked for an in vitro interaction between IVIg and the anti-acetylcholine receptor autoantibodies. Significant inhibition by IVIg of anti-acetylcholine receptor autoantibody activity from 30 MG sera was observed and binding of anti-acetylcholine receptor autoantibodies on IVIg was found for four of five myasthenia gravis sera. These observations suggest that IVIg contains Ig directly binding to and inhibiting pathogenic autoantibodies.
Liblau
R
R
Hopital Necker, Paris, France.
Gajdos
P
P
Bustarret
F A
FA
el Habib
R
R
Bach
J F
JF
Morel
E
E
D000293:Adolescent; D000328:Adult; D000368:Aged; D001323:Autoantibodies / Q000037:antagonists & inhibitors* / Q000097:blood; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D007262:Infusions, Intravenous; D008297:Male; D009157:Myasthenia Gravis / Q000276:immunology / Q000628:therapy*; D011950:Receptors, Cholinergic / Q000276:immunology*; D005719:gamma-Globulins / Q000008:administration & dosage*
D001323:Autoantibodies; D011950:Receptors, Cholinergic; D005719:gamma-Globulins